Derm Pharm Cards Part 2 Flashcards
Aldesleukin MAO and use and major AE
Bind to cell surface IL-2 receptor
Induces proliferation and differentiation of B/T cells, monocytes, macrophages and CTLs
Clinical use: melanoma
Renal failure insufficiency caused by capillary leak syndrome
Carmustin MAO and use
Alkylation and carbamoylation of amino acids
Clinical use: melanoma
Cisplatin MAO, AE, use?
Forms DNA intrastrand crosslinks and adducts
severe nephrotoxicity, myelosuppression, and N/V. Significant ototoxicity (tinnitus and occasionally deafness) reported in children
basal cell carcinoma and squamous cell carcinoma
Cyclophosphamide MAO, AE, use?
Pro-drug of active alkylating moiety
Renal compromise, hemorrhagic cystitis (MESNA is protective), N/V, rashes. Amenorrhea / infertility. Monitor for 2° malignancies. Pulmonary fibrosis.
basal cell carcinoma
Dacarbazine MAO, use?
Pro-drug of active alkylating moiety
Clinical use: melanoma
Imiquimod MAO, use?
Small molecule tumor-directed immune response initiator:
- Direct activation of TLR7 and/or TLR8 activation of NFB upregulation of proinflammatory cytokines
- Adenosine receptor blockade blocks AC cAMP
- Bcl-2/Bax shift & caspase activation apoptosis (at high concentrations)
Clinical use: basal cell carcinoma, actinic keratosis and HPV
Interferon- 2b MAO, use?
Binding to receptor causes signaling through JAK/STAT/IRF-9 and results in increased transcription of >300 genes that inhibit cancer growth, collectively called ISGs
Clinical use: melanoma
Cautiously used in autoimmune diseases, cardiac disease and depression (associated with increased risk of suicidal ideation)
What do the following have in common? Carmustine cisplatin cyclophosphamide dactinomycin doxorubicin lomustine methotrexate
increase risk of secondary malignancy
Sorafenib MAO, use?
Multi-kinase inhibitor:
VEGF, PDGFR, KIT and RAF kinase
Inhibits tumor cell proliferation by targeting the RAF/MEK/ERK pathway at the level of RAF kinase
Exerts an anti-angiogenic effect by targeting the receptor tyrosine kinases VEGFR-2 and PDGFR and their associated signaling
Clinical use: melanoma
Trametinib MAO, use?
Reversible MEK inhibitor for patients with BRAF V6ooE or V600K mutations
Melanoma
Trichloroacetic acid MAO, use?
Rapidly penetrates and cauterizes skin, keratin and other tissues
“Chemical peel”
Clinical use: actinic keratosis
Vismodegib MAO, use?
Oral SMO inhibitor
Lipophilic agent with extensive metabolism
Clinical use: basal cell carcinoma
AE-intrauterine fetal death, male mediated teratogenicity
Vemurafenib
Inhibitor of mutated BRAF, including mutated BRAFV600E
(CONFIRMED by genotyping)
Resistance can occur via alternative pathway activation
Hepatic metabolism, PGP & CYP interactions possible, elevated serum creatinine, elevated liver enzymes, QT prolongation/TP, increased photosensitivity, cutaneous SCC in 1/4th patients and severe dermatologic reactions (SJS) possible
Serious ophthalmologic issues: uveitis, iritis, retinal vein occlusion
Clinical use: melanoma
3 best cytotoxic agents for melanoma
Dacarbazine
Lomustine
Carmustine
3 immunotherapies for melanoma
Aldesleikin (IL-2R agonist)
INF-alpha
Ipilimumab
Ipilimumab
Recombinant antibody that binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) receptor on Tcells and activates them
Bolsters antitumor response of the immune system
Dermatitis including toxic epidermal necrolysis caused by Tcell activation and proliferation
BBW:
Adrenal insufficiency, diarrhea, Guillain-Barre syndrome, hepatitis, hyperthyroidism, hypopituitarism, hypothyroidism, myasthenia gravis, peripheral neuropathy, pregnancy, serious rash
Pregnancy category C
3 signal transduction inhibitors for melanoma
Sorafinib
Vemurafenib
Trametinib
UVA1
340-400nm
increases photo-aging, cancer risk
UVA2
320-340nm
increases photo-aging cancer risk